Ademi Firm Seeks Fair Treatment for VYNE Therapeutics Shareholders Amid Controversial Merger The Ademi Firm is probing VYNE Therapeutics for potential fiduciary breaches following a merger that may unfairly dilute shareholder value.

Ademi Firm Seeks Fair Treatment for VYNE Therapeutics Shareholders Amid Controversial Merger #United_States #Milwaukee #Ademi_Firm #VYNE_Therapeutics #Yarrow_Bioscience